Insider · CIK 0001273213
Anthony E Maida III
Files at OTLC (Oncotelic Therapeutics, Inc.). First filing -, latest -.
In brief
Anthony E Maida III files SEC Form 4 as officer and director at OTLC (Oncotelic Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Anthony E Maida III has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | OTLC Oncotelic Therapeutics, Inc. | AGrant or award Restricted stock Unitsderivative | +1,500 | $0.00 | $0 | 1,500 | Jul 14, 2026 |
Questions about Anthony E Maida III
Answered from the filings on this page, as of the latest one.
Is Anthony E Maida III buying or selling?
Anthony E Maida III has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Anthony E Maida III's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony E Maida III has 0.
Where does Anthony E Maida III file Form 4?
Anthony E Maida III has filed Form 4 at OTLC (Oncotelic Therapeutics, Inc.) as DIRECTOR AND CMO - TRANS. MED.. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.